The Ministry of Industry and Trade of the Russian Federation issued a license to Novo Nordisk LLC for manufacturing finished dosage forms of insulin at the company’s plant in Grabtsevo Industrial Park located in Kaluga region.
The next key production stage comes with the launch of the line to assemble FlexPen, pre-filled multidose disposable injection pens. In 2016, as part of its activities to expand the manufacturing, Novo Nordisk began to build a new shop for assembling the injection pens and invested about 2 billion rubles in the project.
The manufacturing operations at the facility will include the production of aseptic dosage forms, filling cartridges with insulin (manufacturing finished dosage forms), assembling and packing the injection pens. The official launch of the line is scheduled for this mid-November, and the serial manufacturing will start in the first half of 2018.